Sort   by:  
 Page size 
UnknownPhase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518.
Not available
S-EPMC5455764 | biostudies-literature
UnknownCombined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
Not available
S-EPMC4226803 | biostudies-literature
UnknownLong-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.
Not available
S-EPMC10466457 | biostudies-literature
UnknownMolecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma.
Not available
S-EPMC6369924 | biostudies-literature
UnknownThe transcriptional repressor NKAP is required for the development of iNKT cells.
Not available
S-EPMC3615467 | biostudies-literature
UnknownClinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative.
Not available
S-EPMC4639696 | biostudies-literature
UnknownLumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
Not available
S-EPMC4764353 | biostudies-literature
Unknown11th German Conference on Chemoinformatics (GCC 2015) : Fulda, Germany. 8-10 November 2015.
Not available
S-EPMC4896257 | biostudies-literature
UnknownThiazolidinedione use and retinal fluid in the comparison of age-related macular degeneration treatments trials.
Not available
S-EPMC10245276 | biostudies-literature
UnknownTherapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
Not available
S-EPMC8362594 | biostudies-literature
Sort   by:  
 Page size